August 28, 2020 Columns by Ed Tobias Could a Justice Department Lawsuit Threaten Copay Assistance Programs? The U.S. Justice Department has the manufacturer of Copaxone (glatiramer acetate injection) in its crosshairs, and the outcome could have a much greater reach. It appears the case could directly affect the copay help many of us receive for our medications and the patient services some drug companies provide.
December 11, 2019 News by Joana Carvalho, PhD Tysabri May Promote Inflammatory B-Cell Activation in MS Patients, Study Says Tysabri (natalizumab), an effective T-cell targeting treatment for multiple sclerosisĀ (MS),Ā seems to also promote the activation of pro-inflammatory immune B-cells in people with this disease, a studyĀ found. The study, “Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients,” was published in the…
October 2, 2019 News by Patricia Inacio, PhD Profiling Inflammatory Markers in Cerebrospinal Fluid of Importance in Active MS, Case Study Finds Careful profiling of inflammatory markers in cerebrospinal fluid (CSF) of multiple sclerosis patients, coupled with standard exams and scans, helps in understanding disease evolution and treatment response, a case report suggests. It followed aĀ relapsing-remitting multiple sclerosis (RRMS) patient whose inflammatory markers in the CSF remained high over time, and…
August 6, 2018 News by Ana Pena PhD Glatect, Alternative to Copaxone, Added to Public Health Plans of 5 Canadian Provinces Pendopharmās Glatect (glatiramer acetate injection), a lower cost alternative toĀ Tevaās Copaxone, has been added to the public health plans of five Canadian provinces for patients with…
October 9, 2017 News by Alice MelĆ£o, MSc In Blow to Teva, EU Approves Synthonās Generic Version of Copaxone to Treat RRMS Synthonās prefilled syringe with 40 mg/ml of glatiramer acetate ā the generic version of Teva Pharmaceuticalās Copaxone 40 mg ā has received regulatory clearance in all 28 member states of the European Union (EU) plus Iceland, Liechtenstein and Norway to treat relapsing-remitting multiple sclerosis (RRMS). The low-dose…
April 20, 2017 News by Patricia Inacio, PhD Teva to Discuss MS and Huntington’s Therapies at Premier Neurology Conference Teva Pharmaceutical Industries will discuss two of its multiple sclerosis therapies, one that reduces relapses and one that appears to protect nerve structure, at a premier neurology conference in Boston this month. It will also give presentationsĀ at the 2017 Annual Meeting of the American Academy of NeurologyĀ on therapies…
December 7, 2016 News by Patricia Silva, PhD Copaxone Use During Pregnancy by RMS Patients Now Possible in EU European users ofĀ Copaxone (glatiramer acetate injection, Teva Pharmaceutical) to treatĀ relapsing forms of multiple sclerosis (RMS) will no longer see a warning that the drug should not be used during pregnancy. A report assessing this change in the drug’sĀ marketing authorization within the European Union ā a process known as…
September 26, 2016 News by Patricia Silva, PhD Change in Clinical Test Dose of Potential MS Therapy, Laquinimod, Triggers FDA Response Active BiotechĀ acknowledged inĀ an update on laquinimod, the oral small molecule being developed by Teva Pharmaceutical IndustriesĀ to treatĀ multiple sclerosis (MS) and Huntingtonās disease (HD), that the U.S. Food and Drug Administration (FDA) hasĀ rescinded the special protocol assessment given to a Phase 3 study of the treatment in…